[Skip to Content]
[Skip to Content Landing]
June 30, 1978

Estrogens and Cancer

Author Affiliations

University of Maryland Baltimore

JAMA. 1978;239(26):2758-2759. doi:10.1001/jama.1978.03280530022005

To the Editor.—  In 1973 the Coronary Drug Project Research Group reported, on the basis of data available at the time, an apparent excess of cancer deaths among the participants (all men) in the project who had been randomized to treatment with estrogen at a dose of 2.5 mg/day.1 This was one of several reasons for the discontinuation of that treatment. The group promised a follow-up report on the cancer findings.The present report on histologically proved malignant neoplasms, nonfatal and fatal, is based on all data collected prior to the termination of the Coronary Drug Project on Aug 31, 1974, at which time follow-up of participants had been for a minimum of 58 months and an average of 74 months. Because of their high frequency, relatively benign nature, and probable causation from ultraviolet radiation, basal cell carcinomas of the skin were excluded from the analysis. The overall incidence